Werewolf Therapeutics (NASDAQ:HOWL) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Key Points

• Werewolf Therapeutics reported a quarterly earnings per share of ($0.40), exceeding analysts' expectations of ($0.50) by $0.10.
• The company’s stock traded at $1.33, with a market capitalization of $59.68 million and a fifty-two week price range of $0.60 to $4.18.
• Institutional investors own approximately 64.84% of Werewolf Therapeutics shares, with significant increases in holdings from hedge funds during the second quarter.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) posted its earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.10, Zacks reports.

Werewolf Therapeutics Stock Performance

Shares of HOWL stock traded up $0.04 during trading hours on Thursday, hitting $1.28. 97,248 shares of the company's stock traded hands, compared to its average volume of 174,616. Werewolf Therapeutics has a 12-month low of $0.5950 and a 12-month high of $4.18. The stock's fifty day simple moving average is $1.23 and its two-hundred day simple moving average is $1.15. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.30 and a quick ratio of 8.09.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of large investors have recently made changes to their positions in the company. Bank of America Corp DE increased its stake in shares of Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company's stock worth $2,321,000 after purchasing an additional 25,882 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth $409,000. Marshall Wace LLP purchased a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth $113,000. Bridgeway Capital Management LLC increased its stake in shares of Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company's stock worth $111,000 after purchasing an additional 62,414 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new stake in shares of Werewolf Therapeutics in the 1st quarter worth $79,000. 64.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on HOWL shares. JMP Securities lowered their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating on the stock in a research report on Thursday. Wedbush reduced their price objective on Werewolf Therapeutics from $8.00 to $6.00 and set an "outperform" rating on the stock in a research note on Friday, May 9th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Werewolf Therapeutics presently has a consensus rating of "Buy" and an average target price of $8.00.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.